 The FDA has granted accelerated approval to BeiGene Ltds NASDAQ: BGNE Brukinsa zanubrutinib for relapsed or refractory RR marginal zone lymphoma MZL who have received at least one anti-CD20-based regimen. The accelerated approval is based on the overall response rate ORR. 